Figure 2.

Lower 6-bromotryptophan was significantly associated with higher risk of CKD progression. Hazard ratio was estimated per two-fold change in 6-bromotryptophan levels. The reference point (1) is the cut point for tertile 1 of 6-bromotryptophan levels within each cohort. The HRs were estimated from model 3. Covariates in AASK: age, sex, study drug and BP assignment, baseline GFR, CHD, DBP, and APOL1 high-risk status. Covariates in BioMe: age, sex, baseline diabetes and hypertension status, eGFR, CHD, DBP, and APOL1 high-risk status.